{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:51:36Z","timestamp":1781243496666,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.prp.2024.155105","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T11:37:52Z","timestamp":1704800272000},"page":"155105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7\/CK20\/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases"],"prefix":"10.1016","volume":"254","author":[{"given":"Ngoc-Nhu Jennifer","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodorus H.","family":"van der Kwast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle R.","family":"Downes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.prp.2024.155105_bib1","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1097\/PAS.0000000000000238","article-title":"Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference","volume":"38","author":"Epstein","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2024.155105_bib2","unstructured":"National Comprehensive Cancer Network. Prostate Cancer (Version 3.2023). \u3008https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf\u3009 (Accessed 4 September 2023)."},{"key":"10.1016\/j.prp.2024.155105_bib3","unstructured":"National Comprehensive Cancer Network. Bladder Cancer (Version 3.2023). \u3008https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf\u3009 (Accessed 4 September 2023)."},{"issue":"21","key":"10.1016\/j.prp.2024.155105_bib4","first-page":"6111","article-title":"Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression","volume":"60","author":"Bowen","year":"2000","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.prp.2024.155105_bib5","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/00000478-200111000-00007","article-title":"P504S: a new molecular marker for the detection of prostate carcinoma","volume":"25","author":"Jiang","year":"2001","journal-title":"Am. J. Surg. Pathol."},{"issue":"11","key":"10.1016\/j.prp.2024.155105_bib6","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1053\/hupa.2002.129416","article-title":"Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma","volume":"33","author":"Mhawech","year":"2002","journal-title":"Hum. Pathol."},{"issue":"3","key":"10.1016\/j.prp.2024.155105_bib7","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1309\/G6PR-Y774-X738-FG2K","article-title":"Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores","volume":"117","author":"Goldstein","year":"2002","journal-title":"Am. J. Clin. Pathol."},{"issue":"8","key":"10.1016\/j.prp.2024.155105_bib8","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1097\/PAS.0b013e31802f5d33","article-title":"Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma","volume":"31","author":"Chuang","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2024.155105_bib9","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/PAS.0b013e318157020e","article-title":"Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases","volume":"32","author":"Osunkoya","year":"2008","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2024.155105_bib10","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1097\/PAS.0b013e31828d5c32","article-title":"Aberrant expression of p63 in adenocarcinoma of the prostate: a radical prostatectomy study","volume":"37","author":"Giannico","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2024.155105_bib11","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.5858\/arpa.2013-0254-CR","article-title":"Prostate cancer with aberrant diffuse p63 expression: report of a case and review of the literature and morphologic mimics","volume":"137","author":"Wu","year":"2013","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"3","key":"10.1016\/j.prp.2024.155105_bib12","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/modpathol.2014.115","article-title":"Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas","volume":"28","author":"Tan","year":"2015","journal-title":"Mod. Pathol."},{"issue":"12","key":"10.1016\/j.prp.2024.155105_bib13","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/pros.23646","article-title":"ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63","volume":"78","author":"Torres","year":"2018","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.prp.2024.155105_bib14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.path.2022.07.008","article-title":"Prostate cancer: update on grading and reporting","volume":"15","author":"Baraban","year":"2022","journal-title":"Surg. Pathol. Clin."},{"key":"10.1016\/j.prp.2024.155105_bib15","unstructured":"Kench J.G., Kristiansen G., Berney D.M., et al. Prostatic acinar adenocarcinoma. In: WHO Classification of Tumours Editorial Board. Urinary and male genital tumours. Lyon (France): International Agency for Research on Cancer; 2022. (WHO classification of tumours series, 5th ed.; vol. 8). \u3008https:\/\/publications.iarc.fr\/610\u3009."},{"issue":"8","key":"10.1016\/j.prp.2024.155105_bib16","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","article-title":"The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma","volume":"44","author":"van Leenders","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"issue":"2","key":"10.1016\/j.prp.2024.155105_bib17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00000478-199902000-00002","article-title":"Rare expression of high-molecular-weight cytokeratin in adenocarcinoma of the prostate gland: a study of 100 cases of metastatic and locally advanced prostate cancer","volume":"23","author":"Yang","year":"1999","journal-title":"Am. J. Surg. Pathol."},{"issue":"11","key":"10.1016\/j.prp.2024.155105_bib18","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/modpathol.3880220","article-title":"Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma","volume":"13","author":"Genega","year":"2000","journal-title":"Mod. Pathol."},{"issue":"3","key":"10.1016\/j.prp.2024.155105_bib19","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1309\/G1RA-EU9X-X6VV-3W79","article-title":"Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma","volume":"113","author":"Bassily","year":"2000","journal-title":"Am. J. Clin. Pathol."},{"issue":"5","key":"10.1016\/j.prp.2024.155105_bib20","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1309\/V1RY91NKX5ARW2Q5","article-title":"Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and\/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma","volume":"125","author":"Kunju","year":"2006","journal-title":"Am. J. Clin. Pathol."},{"issue":"5","key":"10.1016\/j.prp.2024.155105_bib21","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/pros.24478","article-title":"Expression of high molecular weight cytokeratin-a novel feature of aggressive and innate hormone-refractory prostatic adenocarcinoma","volume":"83","author":"Lu","year":"2023","journal-title":"Prostate"},{"issue":"7","key":"10.1016\/j.prp.2024.155105_bib22","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/his.14901","article-title":"Cribriform morphology is associated with higher risk of biochemical recurrence after radical prostatectomy in patients with Grade Group 5 prostate cancer","volume":"82","author":"Oufattole","year":"2023","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.prp.2024.155105_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2015.10.013","article-title":"Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy","volume":"34","author":"Fajkovic","year":"2016","journal-title":"Urol. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2024.155105_bib24","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/j.clgc.2021.04.009","article-title":"Impact of lymphovascular invasion on overall survival in patients with prostate cancer following radical prostatectomy: stage-per-stage analysis","volume":"19","author":"Jamil","year":"2021","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.prp.2024.155105_bib25","article-title":"'High proliferative cribriform prostate cancer' defines a patient subgroup with an inferior prognosis [published online ahead of print, 2023 Jul 28]","author":"Bogaard","year":"2023","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.prp.2024.155105_bib26","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00418-008-0435-6","article-title":"The human keratins: biology and pathology","volume":"129","author":"Moll","year":"2008","journal-title":"Histochem Cell Biol."},{"issue":"9","key":"10.1016\/j.prp.2024.155105_bib27","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/modpathol.3880175","article-title":"Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases","volume":"13","author":"Chu","year":"2000","journal-title":"Mod. Pathol."},{"issue":"9","key":"10.1016\/j.prp.2024.155105_bib28","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/00000478-200209000-00006","article-title":"Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer","volume":"26","author":"Shah","year":"2002","journal-title":"Am. J. Surg. Pathol."},{"issue":"1","key":"10.1016\/j.prp.2024.155105_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000478-200301000-00001","article-title":"Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas","volume":"27","author":"Parker","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2024.155105_bib30","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0090-4295(97)00684-5","article-title":"Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment","volume":"51","author":"Jiborn","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.prp.2024.155105_bib31","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1200\/JCO.2011.41.5166","article-title":"Challenges in recognizing treatment-related neuroendocrine prostate cancer","volume":"30","author":"Beltran","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2024.155105_bib32","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3389\/fonc.2015.00090","article-title":"Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure","volume":"5","author":"Hu","year":"2015","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2024.155105_bib33","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/his.14707","article-title":"Neuroendocrine differentiation in the setting of prostatic carcinoma: contemporary assessment of a consecutive series","volume":"81","author":"Gopalan","year":"2022","journal-title":"Histopathology"},{"issue":"Pt 3","key":"10.1016\/j.prp.2024.155105_bib34","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.semcancer.2022.05.007","article-title":"Molecular mechanisms underlying the development of neuroendocrine prostate cancer","volume":"86","author":"Liu","year":"2022","journal-title":"Semin Cancer Biol."},{"issue":"2","key":"10.1016\/j.prp.2024.155105_bib35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","article-title":"Clinical and biological features of neuroendocrine prostate cancer","volume":"23","author":"Yamada","year":"2021","journal-title":"Curr. Oncol. Rep."},{"issue":"4","key":"10.1016\/j.prp.2024.155105_bib36","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.path.2022.07.008","article-title":"Prostate cancer: update on grading and reporting","volume":"15","author":"Baraban","year":"2022","journal-title":"Surg. Pathol. Clin."},{"issue":"3","key":"10.1016\/j.prp.2024.155105_bib37","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/PAS.0000000000001557","article-title":"Aberrant GATA3 staining in prostatic adenocarcinoma: a potential diagnostic pitfall","volume":"45","author":"McDonald","year":"2021","journal-title":"Am. J. Surg. Pathol."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824000165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824000165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T08:02:27Z","timestamp":1767168147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033824000165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":37,"alternative-id":["S0344033824000165"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2024.155105","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7\/CK20\/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2024.155105","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"155105"}}